Asset profile
NX-13
Small molecule
Evidence outlook · lead readout
NCT05785715 · Ulcerative Colitis
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT05785715: This randomized, quadruple-blind, placebo-controlled trial tested two NX-13 doses against placebo using a validated disease-activity score, but neither the 250mg nor 750mg dose showed a statistically significant improvement over placebo, and the study was later terminated by the sponsor during its extension phase.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.